Medical Supply Chain Resiliency Act

H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 3193, United States-Republic of Korea Digital Trade Enforcement Act H.R. 4930/S. 2677, To expand the sharing of information with respect to suspected violations of intellectual property rights in trade H.R. 5334/S. 5025, Lindsey O. Graham Sanctioning Russia Act of 2026 H.R. 5926, Mexican Energy Trade Enforcement Act H.R. 6194/S. 2934, Protecting Americans from Russian Litigation Act of 2025 H.R. 6500, AGOA Extension Act H.R. 6504, Haiti Economic Lift Program Extension Act H.R. 8800/S. 4784, National Defense Authorization Act of 2027 S. 3841, Last Sale Valuation Act of 2026 Notice of Request for Comments on the Modernization of the African Growth and Opportunity Act (AGOA), (91 Fed. Reg. 23,142-23,144, April 29, 2026) Advance notice of proposed rulemaking, Heightened Import Disclosures for Supply Chain Visibility (91 Fed. Reg. 56,408-56,414, September 2, 2026) Request for comments, 2026 Review of Notorious Markets for Counterfeiting and Piracy (91 Fed. Reg. 55,154-55,156, August 26, 2026) Various issues relating to implementation of the Inflation Reduction Act, (P.L. 117-169); patent-related issues, including patent linkage, patent term restoration, patent examination practices, and patent quality measures; efforts related to the U.S. International Development Finance Corporation (DFC); efforts related to ensuring a streamlined tariff refund process; efforts related to the advancement of tax treaties with Poland and Croatia; efforts related to identifying unfair foreign trade practices; efforts related to the reauthorization of the African Growth and Opportunity Act (AGOA) (P.L. 106-200), including implementation of Public Law No: 119-75; efforts related to regulations issued by the Bank of Central African States (BEAC); efforts to preserve investment protections such as investor-state dispute settlement; efforts related to outlining critical mineral opportunities with key allies; efforts related to opposing international imposition of digital services taxes; related efforts supporting strong digital trade rules; U.S. economic and commercial relations with key trading partners across the globe; efforts to implement an outbound investment screening mechanism; efforts related to modernizing customs processes and updating tariff application procedures; efforts related to the development of trade relations in the Indo-Pacific; efforts related to the development of trade relations in the Americas region; efforts related to the joint review of the U.S.-Mexico-Canada Agreement (USMCA); implementation and enforcement of U.S. free-trade agreements in force with 20 countries; implementation and enforcement of the agreements and ongoing negotiations of the World Trade Organization (WTO); trade policy concerns regarding customs duties on electronic transmissions; implementation of U.S. sanctions on Russia, including those related to Russias invasion of Ukraine and Public Law No: 119-111; efforts related to sustaining momentum on providing aid to Ukraine; efforts related to reauthorization of the Export-Import Bank (Ex-Im Bank); reforms or changes to export controls; EU Digital Markets Act; EU Digital Services Act; EU Data Act; EU AI Act; IP issues relating to internet counterfeiting and digital piracy; IP issues relating to artificial intelligence; Global Internet Governance; policies and regulations restricting outbound data flows and data transfers; digital-related policies in the G20, G7, OECD, WTO, United Nations, and other international fora; digital trade policy considerations including cross-border data flows, digital service taxes, and issues of forced data localization, and forced disclosure of source code; international trade and regulatory practices impacting digital goods and services; international competition policy and related regulations; international artificial intelligence policy; international 5G policy and telecommunications infrastructure; international cybersecurity policy; international policies on standards development; international policies on data privacy; international policies related to content moderation and intermediary liability; advancing international regulatory cooperation; consumer protection policy and related regulations; digital and tech sovereignty and sovereign cloud; international policies related to online protections for children and minors; IP issues at the World Trade Organization and the World Intellectual Property Organization; the EUs General Pharmaceutical Legislation and provisions related to regulatory data protection and the Bolar exemption; IP issues in Latin America, including enforcement of trade agreements and compulsory licenses and general IP standards and practices in Argentina, Mexico, Brazil, Colombia, the Dominican Republic, and Chile; IP issues in India; pharmaceutical IP issues in the UAE; section 301 investigation on IP issues in Vietnam; USTRs Special 301 report and Review of Notorious Markets for Counterfeiting and Piracy; intersection of tariff-related policy and IP implications; U.S. Patent and Trademark Office IP Attache program; foreign pricing of pharmaceutical products; Most Favored Nation (MFN) reference pricing; USPTO fee setting authority renewal; Federal grants funding and proposed OMB regulatory changes; intellectual property rights enforcement, specifically brands/trademarks; supply chain and defense industrial base issues; development of the National Defense Authorization Act for Fiscal Year 2027

Client expense: $16,480,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Executive Office of the President (EOP), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Security Council (NSC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)

H.R. 2444, Promoting Resilient Supply Chains Act of 2025 H.R. 3838, FY 2026 National Defense Authorization Act H.R. ____, FY 2026 Health and Human Services Appropriations including provisions related to National Institute for Occupational Safety and Health (NIOSH) S. 998, Medical Supply Chain Resiliency Act S. 1639, American Innovation and Jobs Act Discuss draft text of expansion of Make PPE in America Act Issues related to implementation of Make PPE (personal protective equipment) in America Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 4994, ONSHORE Manufacturing Act S. 998, H.R. 2213 Medical Supply Chain Resiliency Act S. 1058, H.R. 2172 Preserving Patients Access to Home Infusion Act H.R. 4559 Prompt and Fair Pay Act H.R. 5031 Preserving Patient Access to Long-Term Care Pharmacies Act S. 709, H.R.1585 Conrad State 30 and Physician Access Reauthorization Act H.R. 483 Health Care Efficiency Through Flexibility Act S. 1460, H.R. 786 Preserving Patient Access to Accountable Care Act S. 1816, H.R. 3514 Improving Seniors' Timely Access to Care Act S. 1600, H.R. 3178 Save Healthcare Workers Act H.R. 2433 Reducing Medically Unnecessary Delays in Care Act S. 2439, H.R. 4731 Resident Physician Shortage Reduction Act H.R. 4464 Preventative Health Savings Act Incentivizing domestic manufacturing of critical medical supplies Issues related to health care costs and transparency Electronic prior authorization and administrative simplification Health care supply chain resiliency 340B Drug discount program Reauthorization of Pandemic and All Hazards Preparedness Act Hospital finance issues Healthcare workforce issues (graduate medical education, health professional training, recruitment and retention, minimum staffing requirements) Medicare payment policies Alternative payment models and related policies Medicare home infusion policy Expanding access to interoperable health tech in long term and post-acute care settings Maternal and infant health Health care workplace violence and worker safety Artificial intelligence in healthcare Cybersecurity and privacy issues for hospitals and health systems CMS annual payment updates for acute and non-acute providers

Client expense: $260,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Medical Supply Chain Resiliency Act (S. 998/HR 2213). Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA).

Client expense: $60,505 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Legislative and executive branch action with respect to tariffs and tariff exclusions on medical products: including Section 122 tariffs and tariff investigations pursuant to Sec 301 and Sec 232 on medical products. Medical Supply Chain Resiliency Act (S. 998/HR 2213)

Client expense: $60,505 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR), White House Office

H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2548/S. 1241, Sanctioning Russia Act of 2025 H.R. 3193, United States-Republic of Korea Digital Trade Enforcement Act H.R. 5926, Mexican Energy Trade Enforcement Act H.R. 6194/S. 2934, Protecting Americans from Russian Litigation Act of 2025 H.R. 6500, AGOA Extension Act H.R. 6504, Haiti Economic Lift Program Extension Act H.R. 8800/S. 4784, National Defense Authorization Act of 2027 S. 3841, Last Sale Valuation Act of 2026 Notice of Request for Comments on the Modernization of the African Growth and Opportunity Act (AGOA), (91 Fed. Reg. 23,142-23,144, April 29, 2026) Various issues relating to implementation of the Inflation Reduction Act, (P.L. 117-169); patent-related issues, including patent linkage, patent term restoration, patent examination practices, and patent quality measures; regulatory data protection; efforts related to the U.S. International Development Finance Corporation (DFC); efforts related to ensuring a streamlined tariff refund process; efforts related to the advancement of tax treaties with Poland and Croatia; efforts related to identifying unfair foreign trade practices; efforts related to the reauthorization of the African Growth and Opportunity Act (AGOA) (P.L. 106-200); efforts related to regulations issued by the Bank of Central African States (BEAC); efforts to preserve investment protections such as investor-state dispute settlement; efforts related to outlining critical mineral opportunities with key allies; efforts related to opposing international imposition of digital services taxes; related efforts supporting strong digital trade rules; efforts to modify permanent normal trade relations treatment with China; U.S. economic and commercial relations with key trading partners across the globe; efforts to implement an outbound investment screening mechanism; efforts related to modernizing customs processes and updating tariff application procedures, including revisions to the de minimis statute; efforts related to the development of trade relations in the Indo-Pacific; efforts related to the development of trade relations in the Americas region; efforts related to the joint review of the U.S.-Mexico-Canada Agreement (USMCA); implementation and enforcement of U.S. free-trade agreements in force with 20 countries; implementation and enforcement of the agreements and ongoing negotiations of the World Trade Organization (WTO); trade policy concerns regarding customs duties on electronic transmissions; implementation of U.S. sanctions on Russia, including those related to Russias invasion of Ukraine; efforts related to sustaining momentum on providing aid to Ukraine; efforts related to reauthorization of the Export-Import Bank (Ex-Im Bank); reforms or changes to export controls; EU Digital Markets Act; EU Digital Services Act; EU Data Act; EU AI Act; IP issues relating to internet counterfeiting and digital piracy; IP issues relating to artificial intelligence; Global Internet Governance; policies and regulations restricting outbound data flows and data transfers; digital-related policies in the G20, G7, OECD, WTO, United Nations, and other international fora; digital trade policy considerations including cross-border data flows, digital service taxes, and issues of forced data localization, and forced disclosure of source code; international trade and regulatory practices impacting digital goods and services; international competition policy and related regulations; international artificial intelligence policy; international 5G policy and telecommunications infrastructure; international cybersecurity policy; international policies on standards development; international policies on data privacy; international digital health policies; international policies related to content moderation and intermediary liability; advancing international regulatory cooperation; consumer protection policy and related regulations; digital and tech sovereignty and sovereign cloud; international policies related to online protections for children and minors; IP issues at the WTO and the World Intellectual Property Organization; the EUs General Pharmaceutical Legislation; IP issues in Latin America, including enforcement of trade agreements and compulsory licenses and general IP standards and practices in Argentina, Mexico, Brazil, Colombia, the Dominican Republic, Vietnam, and Chile; IP issues in India; pharmaceutical IP issues in the UAE; section 301 investigation on IP issues in Vietnam; USTRs Special 301 report and Review of Notorious Markets for Counterfeiting and Piracy; intersection of tariff-related policy and IP implications; U.S. Patent and Trademark Office IP Attache program; foreign pricing of pharmaceutical products; Most Favored Nation (MFN) reference pricing; supply chain and defense industrial base issues; development of the National Defense Authorization Act for Fiscal Year 2027

Client expense: $16,950,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Executive Office of the President (EOP), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Security Council (NSC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)

Tariff policy Customs Enforcement Issues USMCA Enforcement and Review Universal Postal Union Compliance and postal compliance with new postal de minimis rules H.R. 2213/ S.998 - Medical Supply Chain Resiliency Act

Client expense: $1,500,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Small Business Administration (SBA), State, Dept of (DOS), U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office

H.R. 3838, FY 2026 National Defense Authorization Act; H.R. ____, FY 2026 Health and Human Services Appropriations including provisions related to National Institute for Occupational Safety and Health (NIOSH); S. 998, Medical Supply Chain Resiliency Act; S. 1639, American Innovation and Jobs Act; Discuss draft text of expansion of Make PPE in America Act; Issues related to implementation of Make PPE (personal protective equipment) in America Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Continued monitoring and encouraged passage of the Medical Supply Chain Resiliency Act (S.998/HR.2213) Provided education and information on the impact of continued tariffs on the healthcare supply chain

Client expense: $320,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Continued monitoring and encouraged passage of the Medical Supply Chain Resiliency Act (S.998/HR.2213)

Client expense: $320,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to medical supply chains; Issues related to H.R. 2213/S. 998 - Medical Supply Chain Resiliency Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)

Issues related to medical supply chains; Issues related to H.R. 2213/S. 998 - Medical Supply Chain Resiliency Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)

H.R. 2444, Promoting Resilient Supply Chains Act of 2025 H.R. 3838, FY 2026 National Defense Authorization Act H.R. ____, FY 2026 Health and Human Services Appropriations including provisions related to National Institute for Occupational Safety and Health (NIOSH) S. 998, Medical Supply Chain Resiliency Act S. 1639, American Innovation and Jobs Act Discuss draft text of expansion of Make PPE in America Act Issues related to implementation of Make PPE (personal protective equipment) in America Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 998, H.R. 2213 Medical Supply Chain Resiliency Act S. 1058, H.R. 2172 Preseving Patients Access to Home Infusion Act H.R. 4559 Prompt and Fair Pay Act H.R. 5031 Preserving Patient Access to Long-Term Care Pharmacies Act S. 709, H.R.1585 Conrad State 30 and Physician Access Reauthorization Act H.R. 483 Health Care Efficiency Through Flexibility Act S. 1460, H.R. 786 Preserving Patient Access to Accountable Care Act S. 1816, H.R. 3514 Improving Seniors' Timely Access to Care Act S. 1600, H.R. 3178 Save Healthcare Workers Act H.R. 2433 Reducing Medically Unnecessary Delays in Care Act S. 2439, H.R. 4731 Resident Physician Shortage Reduction Act H.R. 4464 Preventative Health Savings Act Incentivizing domestic manufacturing of critical medical supplies Issues related to health care costs and transparency Electronic prior authorization and administrative simplification Health care supply chain resiliency 340B Drug discount program Reauthorization of Pandemic and All Hazards Preparedness Act Hospital finance issues Healthcare workforce issues (graduate medical education, health professional training, recruitment and retention, minimum staffing requirements) Medicare payment policies Alternative payment models and related policies Medicare home infusion policy Reauthorization of Substance-Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act Expanding access to interoperable health tech in long term and post-acute care settings Maternal and infant health Health care workplace violence and worker safety Artificial intelligence in healthcare Medicaid Disproportionate Hospital Share cuts Cybersecurity and privacy issues for hospitals and health systems Comment letters for PFS, OPPS, and HH.

Client expense: $140,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 266 Lorna Breen Healthcare Provider Protection Reauthorization S. 998 Medical Supply Chain Resiliency Act HR 2213 tariffs on medical goods HR 5052/S 547 Train More Nurses Act

Client expense: $240,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE

H.R. 33/S. 199, United States-Taiwan Expedited Double-Tax Relief Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2548/S. 1241, Sanctioning Russia Act of 2025 H.R. 2665/S. 1272, Trade Review Act of 2025 H.R. 3193, United States-Republic of Korea Digital Trade Enforcement Act H.R. 5197/S. 3103, A bill to authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of certain countries H.R. 5926, Mexican Energy Trade Enforcement Act H.R. 6194/S. 2934, Protecting Americans from Russian Litigation Act of 2025 H.R. 6500, AGOA Extension Act H.R. 6504, Haiti Economic Lift Program Extension Act S. 3399, Digital Trade Promotion Act S. 3841, Last Sale Valuation Act of 2026 H.J. Res. 72, Relating to the National Emergency by the President on February 1, 2025 S.J. Res. 77, A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada S.J. Res. 88, A joint resolution terminating the national emergency declared to impose global tariffs Various issues relating to U.S.-Korea digital trade and services; Congressional tariff authority; Adoption and Procedures of the Section 232 Steel and Aluminum Tariff Inclusions Process; reform of the World Trade Organization (WTO); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of the Inflation Reduction Act, (P.L. 117-169); pharmaceutical price controls; patent-related issues, including patent linkage, patent term restoration, patent examination practices, and patent quality measures; regulatory data protection; efforts related to the U.S. International Development Finance Corporation (DFC); efforts related to ensuring a streamlined tariff refund process; efforts related to the advancement of tax treaties with Poland and Croatia; efforts related to identifying unfair foreign trade practices; efforts related to the extension of the African Growth and Opportunity Act (AGOA) (P.L. 106-200); efforts related to regulations issued by the Bank of Central African States (BEAC); efforts to preserve investment protections such as investor-state dispute settlement; efforts related to outlining critical mineral opportunities with key allies; efforts related to opposing international imposition of digital services taxes; efforts related to supporting strong digital trade rules; efforts to modify permanent normal trade relations treatment with China; U.S. economic and commercial relations with key trading partners across the globe; efforts to implement an outbound investment screening mechanism; efforts related to modernizing customs processes and updating tariff application procedures, including revisions to the de minimis statute; efforts related to the development of trade relations in the Indo-Pacific; efforts related to the development of trade relations in the Americas region; efforts related to the joint review of the U.S.-Mexico-Canada Agreement (USMCA); implementation and enforcement of U.S. free-trade agreements in force with 20 countries; implementation and enforcement of the agreements and ongoing negotiations of the WTO; trade policy concerns regarding customs duties on electronic transmissions; implementation of U.S. sanctions on Russia, including those related to Russias invasion of Ukraine; efforts related to sustaining momentum on providing aid to Ukraine; efforts related to reauthorization of the Export-Import Bank (Ex-Im Bank); reforms or changes to export controls; EU Digital Markets Act; EU Digital Services Act; EU Data Act; EU AI Act; IP issues relating to internet counterfeiting and digital piracy; IP issues relating to artificial intelligence; Global Internet Governance; policies and regulations restricting outbound data flows and data transfers; digital-related policies in the G20, G7, OECD, WTO, United Nations, and other international fora; digital trade policy considerations including cross-border data flows, digital service taxes, and issues of forced data localization, and forced disclosure of source code; international trade and regulatory practices impacting digital goods and services; international competition policy and related regulations; international artificial intelligence policy; international 5G policy and telecommunications infrastructure; international cybersecurity policy; international policies on standards development; international policies on data privacy; international digital health policies; international policies related to content moderation and intermediary liability; advancing international regulatory cooperation; consumer protection policy and related regulations; steel and aluminum tariffs; digital and tech sovereignty and sovereign cloud; IP issues at the WTO and the World Intellectual Property Organization; the EUs General Pharmaceutical Legislation; IP issues in Latin America, including enforcement of trade agreements and compulsory licenses and general IP standards and practices in Argentina, Mexico, Brazil, Colombia, and Chile; IP issues in India; USTRs Special 301 report and Review of Notorious Markets for Counterfeiting and Piracy; intersection of tariff-related policy and IP implications; U.S. Patent and Trademark Office IP Attache program; imposition of potential patent valuation fees; foreign pricing of pharmaceutical products; Most Favored Nation (MFN) reference pricing; ongoing practice of discretionary denials at the Patent Trial and Appeal Board; international competition policy, specifically FTC and DOJ involvement in the European Unions implementation of the EU Digital Markets Act; International Emergency Economic Powers Act (50 U.S.C. 1701(a)(b)) (IEEPA); IEEPA tariff refund implementation following the Supreme Courts decision in Learning Resources v. Trump; Directive (EU) 2024/2853 of the European Parliament and of the Council of 23 October 2024 on liability for defective products and repealing Council Directive 85/374/EEC; Mexicos Tax Administration Service (SAT); recommended changes to the EUs Corporate Sustainability Due Diligence Directive (CS3D); supply chain and defense industrial base issues; development of the National Defense Authorization Act for Fiscal Year 2027

Client expense: $19,750,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Executive Office of the President (EOP), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Security Council (NSC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)

Medical Supply Chain Resiliency Act (S. 998/HR 2213). Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA).

Client expense: $67,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Legislative and executive branch action with respect to tariffs and tariff exclusions on medical products: including Section 122 tariffs and tariff investigations pursuant to Sec 301 and Sec 232 on medical products. Medical Supply Chain Resiliency Act (S. 998/HR 2213)

Client expense: $67,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR), White House Office

S. 266 Lorna Breen Healthcare Provider Protection Reauthorization S. 998 Medical Supply Chain Resiliency Act HR 2213 tariffs on medical goods HR 5052/S 547 Train More Nurses Act

Client expense: $240,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE

Continued monitoring and encouraged passage of the Medical Supply Chain Resiliency Act (S.998/HR.2213)

Client expense: $320,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Continued monitoring and encouraged passage of the Medical Supply Chain Resiliency Act (S.998/HR.2213)

Client expense: $320,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 33/S. 199, United States-Taiwan Expedited Double-Tax Relief Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2548/S. 1241, Sanctioning Russia Act of 2025 H.R. 2665/S. 1272, Trade Review Act of 2025 H.R. 3193, United States-Republic of Korea Digital Trade Enforcement Act H.R. 5197/S. 3103, A bill to authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of certain countries H.R. 5926, Mexican Energy Trade Enforcement Act H.R. 6194/S. 2934, Protecting Americans from Russian Litigation Act of 2025 H.R. 6500, AGOA Extension Act H.R. 6504, Haiti Economic Lift Program Extension Act S. 3399, Digital Trade Promotion Act S. 3841, Last Sale Valuation Act of 2026 H.J. Res. 72, Relating to the National Emergency by the President on February 1, 2025 S.J. Res. 77, A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada S.J. Res. 88, A joint resolution terminating the national emergency declared to impose global tariffs Various issues relating to U.S.-Korea digital trade and services; Congressional tariff authority; Adoption and Procedures of the Section 232 Steel and Aluminum Tariff Inclusions Process; reform of the World Trade Organization (WTO); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of the Inflation Reduction Act, (P.L. 117-169); pharmaceutical price controls; patent-related issues, including patent linkage, patent term restoration, patent examination practices, and patent quality measures; regulatory data protection; efforts related to the U.S. International Development Finance Corporation (DFC); efforts related to ensuring a streamlined tariff refund process; efforts related to the advancement of tax treaties with Poland and Croatia; efforts related to identifying unfair foreign trade practices; efforts related to the extension of the African Growth and Opportunity Act (AGOA) (P.L. 106-200); efforts related to regulations issued by the Bank of Central African States (BEAC); efforts to preserve investment protections such as investor-state dispute settlement; efforts related to outlining critical mineral opportunities with key allies; efforts related to opposing international imposition of digital services taxes; efforts related to supporting strong digital trade rules; efforts to modify permanent normal trade relations treatment with China; U.S. economic and commercial relations with key trading partners across the globe; efforts to implement an outbound investment screening mechanism; efforts related to modernizing customs processes and updating tariff application procedures, including revisions to the de minimis statute; efforts related to the development of trade relations in the Indo-Pacific; efforts related to the development of trade relations in the Americas region; efforts related to the joint review of the U.S.-Mexico-Canada Agreement (USMCA); implementation and enforcement of U.S. free-trade agreements in force with 20 countries; implementation and enforcement of the agreements and ongoing negotiations of the WTO; trade policy concerns regarding customs duties on electronic transmissions; implementation of U.S. sanctions on Russia, including those related to Russias invasion of Ukraine; efforts related to sustaining momentum on providing aid to Ukraine; efforts related to reauthorization of the Export-Import Bank (Ex-Im Bank); reforms or changes to export controls; EU Digital Markets Act; EU Digital Services Act; EU Data Act; EU AI Act; IP issues relating to internet counterfeiting and digital piracy; IP issues relating to artificial intelligence; Global Internet Governance; policies and regulations restricting outbound data flows and data transfers; digital-related policies in the G20, G7, OECD, WTO, United Nations, and other international fora; digital trade policy considerations including cross-border data flows, digital service taxes, and issues of forced data localization, and forced disclosure of source code; international trade and regulatory practices impacting digital goods and services; international competition policy and related regulations; international artificial intelligence policy; international 5G policy and telecommunications infrastructure; international cybersecurity policy; international policies on standards development; international policies on data privacy; international digital health policies; international policies related to content moderation and intermediary liability; advancing international regulatory cooperation; consumer protection policy and related regulations; steel and aluminum tariffs; digital and tech sovereignty and sovereign cloud; IP issues at the WTO and the World Intellectual Property Organization; the EUs General Pharmaceutical Legislation; IP issues in Latin America, including enforcement of trade agreements and compulsory licenses and general IP standards and practices in Argentina, Mexico, Brazil, Colombia, and Chile; IP issues in India; USTRs Special 301 report and Review of Notorious Markets for Counterfeiting and Piracy; intersection of tariff-related policy and IP implications; U.S. Patent and Trademark Office IP Attache program; imposition of potential patent valuation fees; foreign pricing of pharmaceutical products; Most Favored Nation (MFN) reference pricing; ongoing practice of discretionary denials at the Patent Trial and Appeal Board; international competition policy, specifically FTC and DOJ involvement in the European Unions implementation of the EU Digital Markets Act; International Emergency Economic Powers Act (50 U.S.C. 1701(a)(b)) (IEEPA); IEEPA tariff refund implementation following the Supreme Courts decision in Learning Resources v. Trump; Directive (EU) 2024/2853 of the European Parliament and of the Council of 23 October 2024 on liability for defective products and repealing Council Directive 85/374/EEC; Mexicos Tax Administration Service (SAT); recommended changes to the EUs Corporate Sustainability Due Diligence Directive (CS3D); supply chain and defense industrial base issues; development of the National Defense Authorization Act for Fiscal Year 2027

Client expense: $19,750,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Executive Office of the President (EOP), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Security Council (NSC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)

H.R. 3838, FY 2026 National Defense Authorization Act; H.R. ____, FY 2026 Health and Human Services Appropriations including provisions related to National Institute for Occupational Safety and Health (NIOSH); S. 998, Medical Supply Chain Resiliency Act; S. 1639, American Innovation and Jobs Act; Discuss draft text of expansion of Make PPE in America Act; Issues related to implementation of Make PPE (personal protective equipment) in America Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Tariff policy USMCA Enforcement and Review Universal Postal Union Compliance with new postal de minimis rules H.R. 2213/ S.998 - Medical Supply Chain Resiliency Act

Client expense: $1,910,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Small Business Administration (SBA), State, Dept of (DOS), U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office

H.R. 2444, Promoting Resilient Supply Chains Act of 2025 H.R. 3838, FY 2026 National Defense Authorization Act H.R. ____, FY 2026 Health and Human Services Appropriations including provisions related to National Institute for Occupational Safety and Health (NIOSH) S. 998, Medical Supply Chain Resiliency Act S. 1639, American Innovation and Jobs Act Discuss draft text of expansion of Make PPE in America Act Issues related to implementation of Make PPE (personal protective equipment) in America Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to medical supply chains; Issues related to H.R. 2213 / S. 998 - Medical Supply Chain Resiliency Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)

Issues related to medical supply chains; Issues related to H.R. 2213 / S. 998 - Medical Supply Chain Resiliency Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)

S. 998, H.R. 2213 Medical Supply Chain Resiliency Act S. 1058, H.R. 2172 Preseving Patients Access to Home Infusion Act H.R. 4559 Prompt and Fair Pay Act H.R. 5031 Preserving Patient Access to Long-Term Care Pharmacies Act S. 709, H.R.1585 Conrad State 30 and Physician Access Reauthorization Act H.R. 483 Health Care Efficiency Through Flexibility Act S. 1460, H.R. 786 Preserving Patient Access to Accountable Care Act S. 1816, H.R. 3514 Improving Seniors' Timely Access to Care Act S. 1600, H.R. 3178 Save Healthcare Workers Act H.R. 2433 Reducing Medically Unnecessary Delays in Care Act S. 2439, H.R. 4731 Resident Physician Shortage Reduction Act H.R. 4464 Preventative Health Savings Act Incentivizing domestic manufacturing of critical medical supplies Issues related to health care costs and transparency Electronic prior authorization and administrative simplification Health care supply chain resiliency 340B Drug discount program Reauthorization of Pandemic and All Hazards Preparedness Act Hospital finance issues Healthcare workforce issues (graduate medical education, health professional training, recruitment and retention, minimum staffing requirements) Medicare payment policies Alternative payment models and related policies Medicare home infusion policy Reauthorization of Substance-Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act Expanding access to interoperable health tech in long term and post-acute care settings Maternal and infant health Health care workplace violence and worker safety Artificial intelligence in healthcare Medicaid Disproportionate Hospital Share cuts Cybersecurity and privacy issues for hospitals and health systems Comment letters for PFS, OPPS, and HH.

Client expense: $220,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Medical Supply Chain Resiliency Act (S. 998/HR 2213). Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA).

Client expense: $67,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Legislative and executive branch action with respect to tariffs and tariff exclusions on medical products: including Section 122 tariffs and tariff investigations pursuant to Sec 301 and Sec 232 on medical products. Medical Supply Chain Resiliency Act (S. 998/HR 2213)

Client expense: $67,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR), White House Office

Imports of personal protective equipment (PPE), medical consumables, and medical equipment, including Devices: Monitored and provided feedback on U.S. Department of Commerces Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Personal Protective Equipment, Medical Consumables, and Medical Equipment, Including Devices (Docket No: 250924-0160; XRIN 0694-XC134) Continued monitoring and encouraged passage of the Medical Supply Chain Resiliency Act (S.998/HR.2213)

Client expense: $320,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE

S. 998, H.R. 2213 Medical Supply Chain Resiliency Act S. 1058, H.R. 2172 Preseving Patients Access to Home Infusion Act H.R. 4559 Prompt and Fair Pay Act H.R. 5031 Preserving Patient Access to Long-Term Care Pharmacies Act S. 709, H.R.1585 Conrad State 30 and Physician Access Reauthorization Act H.R. 483 Health Care Efficiency Through Flexibility Act S. 1460, H.R. 786 Preserving Patient Access to Accountable Care Act S. 1816, H.R. 3514 Improving Seniors' Timely Access to Care Act S. 1600, H.R. 3178 Save Healthcare Workers Act H.R. 2433 Reducing Medically Unnecessary Delays in Care Act S. 2439, H.R. 4731 Resident Physician Shortage Reduction Act H.R. 4464 Preventative Health Savings Act Incentivizing domestic manufacturing of critical medical supplies Issues related to health care costs and transparency Electronic prior authorization and administrative simplification Health care supply chain resiliency 340B Drug discount program Reauthorization of Pandemic and All Hazards Preparedness Act Hospital finance issues Healthcare workforce issues (graduate medical education, health professional training, recruitment and retention, minimum staffing requirements) Medicare payment policies Alternative payment models and related policies Medicare home infusion policy Reauthorization of Substance-Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act Expanding access to interoperable health tech in long term and post-acute care settings Maternal and infant health Health care workplace violence and worker safety Artificial intelligence in healthcare Medicaid Disproportionate Hospital Share cuts Cybersecurity and privacy issues for hospitals and health systems Comment letters for PFS, OPPS, and HH.

Client expense: $190,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 2444, Promoting Resilient Supply Chains Act of 2025 H.R. 3838, FY 2026 National Defense Authorization Act H.R. ____, FY 2026 Health and Human Services Appropriations including provisions related to National Institute for Occupational Safety and Health (NIOSH) S. 998, Medical Supply Chain Resiliency Act S. 1639, American Innovation and Jobs Act Discuss draft text of expansion of Make PPE in America Act Issues related to implementation of Make PPE (personal protective equipment) in America Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Tariff policy USMCA Enforcement and Review Universal Postal Union Compliance with new postal de minimis rules S. 2725 - STOP Act 2.0 - Requires increased compliance with AED requirements in the STOP Act; Increased reporting requirements H.R. 2213/ S.998 - Medical Supply Chain Resiliency Act

Client expense: $1,210,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Small Business Administration (SBA), State, Dept of (DOS), U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office

H.R. 1, the One Big, Beautiful Bill Act Improving seniors' timely access to care act (S. 1816 / H.R. 3514) Genomic Data Protection Act Tariffs S. 998, Medical Supply Chain Resiliency Act PAMA reform S 1399, the Health Tech Investment Act H.R. 3580, the Oversight of Medicare Billing Code Cost Act S. 1916 - Protect Genetic information after bankruptcy S 1830 - HHS has no authority to regulate the practice of medicine LCD legislation HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts HR 5392, the Timely Access to Coverage Decisions Act of 2023 Remote digital telepathology HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 3248 - Diagnostic Lab Testing Transparency Act HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act Gene Therapy PREVAIL HR 6371 - budget neutrality bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S. 1546/H.R. 3152 The Patent Eligibility Restoration Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act Cures 2.1 S. 4935, Physician Fee Stabilization Act Medical Lab Personnel Shortage Relief Act S. 709/H.R. 1585 - Conrad State 30 and Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes. H.R. 1968 - Continuing Resolution H.R. 1201 - Doctors in our Borders Act Issues relating to regulation of laboratory diagnostics Patent Eligibility Restoration Act CDC Division of Cancer Prevention and Control and cancer registries appropriations S. 2439 and H.R. 4731, Resident Physician Shortage Reduction Act H.R.5371 - Continuing Appropriations and Extensions Act, 2026 HR 3164 - Ensuring Community Access to Pharmacy Services Act (ECAPS) S 2800 - Pharmacy and Medically Underserved Areas Enhancement Act S 2420 / H.R. 4710 - No Surprises Act Enforcement Act S 2793 - Ensuring Access to Essential Providers Act of 2025 H.R. 5582 / S 2355 - Patients Deserve Price Tags Act Issues related to tariffs Issues related to public health

Client expense: $154,425 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 33/S. 199, United States-Taiwan Expedited Double-Tax Relief Act H.R. 661, MIRACLE Medical Technology Act H.R. 953, United States Trade Leadership in the Indo-Pacific Act H.R. 1743/S. 776, UNITED Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2675, Protecting Our Courts from Foreign Manipulation Act H.R. 3838, Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026 H.R. 3941, To repeal the Caesar Syria Civilian Protection Act of 2019 H.R. 4215, International Traffic in Arms Regulations Licensing Reform Act H.R. 4216, Made-In-America Defense Act H.R. 4233, AUKUS Reform for Military Optimization & Review ARMOR Act S. 2296, National Defense Authorization Act for Fiscal Year 2026 S. 3399, A bill to authorize the President to enter into digital trade agreements, and for other purposes S.J.Res. 37, A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada Various issues related to implementation of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; reform of the World Trade Organization; Committee on Foreign Investment in the United States (CFIUS) concerns, specifically regarding the U.S. international exchange programs; negotiations with the International Monetary Fund; reauthorization of the U.S. International Development Finance Corporation; implementation of the One Big Beautiful Bill Act, (P.L. 119-21); United States-Brazil Critical Minerals Cooperation; supply chain and the defense industrial base; Foreign Assistance Act for Fiscal Year 2026

Client expense: $17,960,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)

H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2270, Empowering Employer Child and Elder Care Solutions Act H.R. 2528/S. 1847, Association Health Plans Act H.R. 6703, Lower Health Care Premiums for All Americans Act, including provisions excluding PBM transparency reform S. 2828, Child Care Modernization Act of 2025 Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), association health plans (AHPs), cost sharing reduction payments (CSRs), individual health reimbursement arrangements (ICHRAs), employer mandates; implementation of the Inflation Reduction Act (P.L. 117-169); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); balance or surprise billing and related issues; single-payer health care options; Affordable Care Act tax credits; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High-Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; expansion of the list of preventive care benefits that may be provided by a high-deductible health plan (HDHP); efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, pooled procurement mechanisms, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance infectious diseases, and non-communicable diseases; support for continued and reformed U.S. foreign assistance, including in global health

Client expense: $17,960,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR)

H.R. 33/S. 199, United States-Taiwan Expedited Double-Tax Relief Act H.R. 953, United States Trade Leadership in the Indo-Pacific Act H.R. 1625, the HELP Extension Act H.R. 1743/S. 776, Undertaking Negotiations on Investment and Trade for Economic Dynamism (UNITED) Act H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 2548/S. 1241, Sanctioning Russia Act of 2025 H.R. 2665/S. 1272, Trade Review Act of 2025 H.R. 3193, United States-Republic of Korea Digital Trade Enforcement Act H.R. 5197/S. 3103, A bill to authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of certain countries H.R. 5926, Mexican Energy Trade Enforcement Act H.R. 6194/S. 2934, Protecting Americans from Russian Litigation Act of 2025 H.R. 6500, AGOA Extension Act H.R. 6504, Haiti Economic Lift Program Extension Act S. 2296, National Defense Authorization Act for Fiscal Year 2026 S. 3399, Digital Trade Promotion Act S.J.Res. 77, A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada S.J.Res. 88, A joint resolution terminating the national emergency declared to impose global tariffs S.J.Res. 37, A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada S.J.Res. 49, A joint resolution terminating the national emergency declared to impose global tariffs Draft legislation titled Haitian Hemispheric Opportunity through Partnership Encouragement Act Draft legislation titled AGOA Renewal and Improvement Act Draft legislation titled the Americas Act Proposed Rule, Federal Trade Commission; Business Opportunity Rule (16 CFR 437, January 13, 2025) Advanced Notice of Proposed Rulemaking, Federal Trade Commission; Earnings Claims Rule Regarding Multi-Level Marketing (Additional Provisions) (16 CFR Part 462, January 13, 2025) Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients (90 Fed. Reg. 15,951-15,952, April 16, 2025) Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Personal Protective Equipment, Medical Consumables, and Medical Equipment, Including Devices (90 Fed. Reg. 46,383, September 26, 2025) Various issues relating to U.S.-Korea digital trade and services; Generalized System of Preferences (GSP) reauthorization; Adoption and Procedures of the Section 232 Steel and Aluminum Tariff Inclusions Process; fifty-percent (50%) tariff on imports from Brazil; ratification of the Assignment of Receivables in International Trade Convention; reform of the World Trade Organization (WTO); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the One Big Beautiful Bill Act, (P.L. 119-21); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of the Uyghur Forced Labor Prevention Act (UFLPA) (P.L. 117-78); implementation of the African Growth and Opportunity Act (P.L. 106-200); implementation of the Inflation Reduction Act, (P.L. 117-169); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); pharmaceutical price controls; implementation of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent-related issues, including patent linkage, patent term restoration, patent examination practices, and patent quality measures; regulatory data protection; efforts related to identifying unfair foreign trade practices; efforts related to the reauthorization of the African Growth and Opportunity Act (AGOA) (P.L. 106-200); efforts related to the reauthorization of the U.S. International Development Finance Corporation (DFC); efforts related to the advancement of tax treaties with Poland and Croatia; efforts related to regulations issued by the Bank of Central African States (BEAC); efforts related to the National Defense Authorization Act for Fiscal Year 2026; efforts to preserve investment protections such as investor-state dispute settlement; efforts related to outlining critical mineral opportunities with key allies; efforts related to opposing international imposition of digital services taxes; related efforts supporting strong digital trade rules; efforts to modify permanent normal trade relations treatment with China; U.S. economic and commercial relations with key trading partners across the globe; efforts to draft and implement an outbound investment screening mechanism; efforts related to establishing a domestic carbon border tax mechanism, foreign pollution fees; efforts related to modernizing customs processes and updating tariff application procedures, including revisions to the de minimis statute; efforts related to the development of trade relations in the Indo-Pacific; efforts related to the development and negotiation of the U.S.-Taiwan Initiative on 21st Century Trade; efforts related to the development of trade relations in the Americas region; efforts related to the development and negotiation of the U.S.-UK Dialogue on the Future of Atlantic Trade; efforts related to the development and negotiation of the U.S.-Kenya Strategic Trade and Investment Partnership; efforts related to the joint review of the U.S.-Mexico-Canada Agreement (USMCA); implementation and enforcement of U.S. free-trade agreements in force with Canada and Mexico (the United States-Mexico-Canada Agreement), the Dominican Republic-Central America Free Trade Agreement (CAFTA-DR FTA), Colombia and South Korea; implementation and enforcement of the agreements and ongoing negotiations of the World Trade Organization (WTO); efforts to significantly revise U.S. antidumping and countervailing duty law; Trade Promotion Authority (TPA) reauthorization and reform; U.S.-EU energy and sustainability cooperation; EU and international tax policy including digital tax proposals; U.S.-EU negotiations on a legal data transfer mechanism; U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; EU Data Act; EU AI Act; European Cybersecurity Certification Scheme for Cloud Services (EUCS); EU Carbon Border Adjustment Mechanism; China's intellectual property regime, industrial policies, and cyber security; implementation of the U.S.-China economic and trade agreement; United States-India Trade Policy Forum and associated bilateral trade negotiations; efforts related to sustaining momentum on providing aid to Ukraine; efforts to provide financial support, trade facilitation, and infrastructure support to the African Continental Free Trade Area (AfCFTA); IP issues relating to internet counterfeiting and digital piracy; IP issues relating to artificial intelligence; implementation of U.S. sanctions on Russia, including those related to Russias threats to and invasion of Ukraine; reforms to export controls; Global Internet Governance; network fees; Global Cross Border Privacy Rules Forum; policies and regulations restricting outbound data flows and data transfers; digital-related policies in the G20, G7, OECD, WTO, United Nations, and other international fora; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; efforts to modernize the Committee on Foreign Investment in the United States (CFIUS); efforts related to the Export-Import Bank (Ex-Im Bank); digital trade policy considerations including cross-border data flows, digital service taxes, and issues of forced data localization, and forced disclosure of source code; international trade and regulatory practices impacting digital goods and services; international competition policy and related regulations; international artificial intelligence policy; international 5G policy and telecommunications infrastructure; international cybersecurity policy; international policies on standards development; international policies on data privacy; international digital health policies; international policies related to content moderation and intermediary liability; advancing international regulatory cooperation; consumer protection policy and related regulations; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; digital and tech sovereignty and sovereign cloud; tariff authority letter supporting Congress reclaiming its constitutional tariff authority; U.S.-Brazil trade; U.S.-Columbia Trade Promotion Agreement; Pacific Digital Trade Agreements; U.S.-Chile Tax Treaty, Convention for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital; U.S. Trade Representative section 301 investigation of Frances digital services tax; efforts to pass the Miscellaneous Tariff bill; Russian sovereign debt; Commercial Service Office in Bangladesh; Indo-Pacific Economic Framework and associated issues, digital trade de minimis level for duty free clearance of low value goods, competition provisions; recommendations for Export Controls Cooperation at the U.S.-EU Trade and Technology Council; adoption of digital clothing labels; IP issues at the World Trade Organization and the World Intellectual Property Organization; the EUs General Pharmaceutical Legislation; IP issues in Latin America, including enforcement of trade agreements and compulsory licenses and general IP standards and practices in Brazil and Chile; IP issues in India; USTRs Special 301 report and Review of Notorious Markets for Counterfeiting and Piracy; intersection of tariff-related policy and IP implications; U.S. Patent and Trademark Office IP Attache program; issues related to the imposition of potential patent valuation fees; issues related to the ongoing practice of discretionary denials at the Patent Trial and Appeal Board; international competition policy, specifically FTC and DOJ involvement in the European Unions implementation of the EU Digital Markets Act; proposal for General License Authorizing Private Commercial Arbitration Proceedings Involving Blocked Persons; The United States Trade Representatives decision to withdraw support for digital trade in the context of World Trade Organizations e-commerce negotiations; support for robust global framework for facilitation of digital trade through the ongoing joint statement initiative on e-commerce (JSI); Indonesia Ministry of Trade Import Licensing Regulations; International Emergency Economic Powers Act (50 U.S.C. 1701(a)(b)) (IEEPA); conduction of South Africas competition reviews; 2019 Agreement Suspending the Antidumping Investigation on Fresh Tomatoes from Mexico; continuation of the Moratorium on Customs Duties on Electronic Transmissions; recommended changes to the EUs Corporate Sustainability Due Diligence Directive (CS3D); Executive Order 14193, Imposing Duties to Address the Flow of Illicit Drugs Across Our Northern Border; supply chain and defense industrial base issues; Foreign Assistance Act for Fiscal Year 2026

Client expense: $17,960,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Executive Office of the President (EOP), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Security Council (NSC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)

H.R. 2444, Promoting Resilient Supply Chains Act of 2025 H.R. 3838, FY 2026 National Defense Authorization Act H.R. ____, FY 2026 Health and Human Services Appropriations including provisions related to National Institute for Occupational Safety and Health (NIOSH) S. 998, Medical Supply Chain Resiliency Act S. 1639, American Innovation and Jobs Act Discuss draft text of expansion of Make PPE in America Act Issues related to implementation of Make PPE (personal protective equipment) in America Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.998 - Medical Supply Chain Resiliency Act Section 232 tariffs on pharmaceuticals Section 301 investigations Comments for USTR 2026 National Trade Estimate (NTE) report (tariff and non-tariff barriers) Supply Chain and trade barriers that need addressing (National Security Commission on Emerging Biotechnology) Department of Commerce Bureau of Industry and Security API survey Issues related to critical supply chains reshoring investments Issues related to importation of drugs Most favored nation policies related to pharmaceuticals Tariffs/trade policies related to tariffs on pharmaceuticals Issues related to direct-to-consumer advertising by pharmaceutical manufacturers Trade and tariffs (general education, country-specific tariffs, sector-specific tariffs) Pharmaceutical manufacturing (general education)

Client expense: $670,000 · Firm income: Not reported

Government targets: Bureau of Industry and Security (BIS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, U.S. Trade Representative (USTR)

Issues related to medical supply chains; Issues related to H.R. 2213/S. 998 - Medical Supply Chain Resiliency Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)

Issues related to medical supply chains; Issues related to H.R. 2213/S. 998 - Medical Supply Chain Resiliency Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)

Medical Supply Chain Resiliency Act (S. 998/HR 2213). Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) either as standalone legislation or inclusion in a larger package such as S.891, the Bipartisan Health Care Act.

Client expense: $30,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), Federal Maritime Commission, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Transportation, Dept of (DOT), White House Office

Legislative and executive branch action with respect to tariffs and tariff exclusions on medical products: including IEEPA reciprocal tariffs, IEEPA border/fentanyl tariffs on China, Mexico and Canada, tariff investigations pursuant to Sec 301 and Sec 232 on medical products. Medical Supply Chain Resiliency Act (S. 998/HR 2213)

Client expense: $30,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)